

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 November 2009 (05.11.2009)

PCT

(10) International Publication Number
WO 2009/134469 A1

(51) International Patent Classification:

C07H 19/073 (2006.01) C12Q 1/68 (2006.01)
C07H 21/04 (2006.01) C07H 19/173 (2006.01)

(21) International Application Number:

PCT/US2009/031297

(22) International Filing Date:

16 January 2009 (16.01.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/048,808 29 April 2008 (29.04.2008) US
61/136,732 29 September 2008 (29.09.2008) US

(71) Applicant (for all designated States except US): **LIFE TECHNOLOGIES** [US/US]; 850 Lincoln Centre Drive, Foster City, CA 94404 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MENCHEN, Steven, M.** [US/US]; 768 Vanda Way, Fremont, CA 94536 (US). **ROSENBLUM, Barnett** [US/US]; 1521 Estelle Avenue, San Jose, CA 95118 (US). **KENNEY, Paul** [US/US]; 1025 Payette Avenue, Sunnyvale, CA 94087 (US). **KHAN, Shoeb, I.** [US/US]; 651 Catamara Street, Apt. #1, Foster City, CA 94404 (US). **MA, Zhaochun** [CN/US]; 1091 Blair Avenue, Sunnyvale, CA 94087 (US). **CHEN, Jer-kang** [US/US]; 882 Ames Avenue, Palo Alto, CA 94303 (US). **LAM, Joseph** [US/US]; 7867 Pineville Circle, Castro Valley, CA 94552 (US).

HUANG, Boli [CN/US]; 4173 E1 Camino Real, #27, Palo Alto, CA 94306 (US).

(74) Agent: **RAIMUND, Christopher, W.**; Morris, Manning & Martin, LLP, 1333 H Street, N.W., Suite 820, Washington, DC 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: UNNATURAL POLYMERASE SUBSTRATES THAT CAN SUSTAIN ENZYMATIC SYNTHESIS OF DOUBLE STRANDED NUCLEIC ACIDS FROM A NUCLEIC ACID TEMPLATE AND METHODS OF USE

(57) Abstract: Nucleotide analogs that can sustain the enzymatic synthesis of double-stranded nucleic acid from a nucleic template are described. The nucleotide analogs include: (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine, uracil and their analogs; (ii) a label attached to the base or analog of the base via a cleavable linker; (iii) a deoxyribose; and (iv) one or more phosphate groups. The linker and/or the label inhibits template directed polymerase incorporation of a further nucleotide substrate onto an extended primer strand. In addition, cleavage of the linker leaves a residue attached to the base which is not present in the natural nucleotide and which does not inhibit extension of the primer strand. The nucleotide analogs can therefore be used as reversible terminators in sequencing by synthesis methods without blocking the 3' hydroxyl group. Methods of sequencing DNA using the substrates are also described.



WO 2009/134469 A1

TITLE**UNNATURAL POLYMERASE SUBSTRATES THAT CAN SUSTAIN
ENZYMATIC SYNTHESIS OF DOUBLE STRANDED NUCLEIC ACIDS
FROM A NUCLEIC ACID TEMPLATE AND METHODS OF USE**

[0001] This application claims the benefit of Provisional U.S. Patent Application Serial No. 61/048,808, filed on April 29, 2008 and Provisional U.S. Patent Application Serial No. 61/136,732, filed on September 29, 2008. Each of the aforementioned applications is incorporated by reference herein in its entirety.

[0002] Pursuant to the provisions of 37 C.F.R. §1.52(e)(5), the sequence listing text file named 69360_Seq_Listing.txt, created on January 16, 2009 and having a size of 7,129 bytes, and which is being submitted herewith, is incorporated by reference herein in its entirety.

[0003] *The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described herein in any way.*

Field

[0004] This application relates generally to polymerase substrates and to methods of sequencing nucleic acids such as DNA or RNA using the substrates.


Introduction

[0005] Nucleic acid sequencing typically involves cloning the nucleic acid of interest to prepare bulk samples of defined nucleic acid fragments followed by analysis of the bulk nucleic acids. Sequencing by synthesis has been proposed as a method to achieve fast *de novo* sequencing. Sequencing by synthesis can involve the analysis of an ensemble of amplified single molecules of nucleic acid, or the analysis of single molecules of nucleic acid and can theoretically be used to examine native genomic DNA without the need for bacterial cloning or other forms of amplification.

[0006] There still exists a need, however, for improved methods of sequencing by synthesis and single molecule nucleic acid sequencing.

SUMMARY

[0007] A compound represented by the following formula (I) is provided:



wherein:

B is a base selected from the group consisting of adenine, guanine, cytosine, uracil, thymine, or their respective analogs;

L₁ is a group that forms a linkage between the base B and F;

F is a heteroatom that forms a linkage between L₁ and L₂;

L₂ is a chemically labile group with respect to its attachment to F and forms a chemical linkage to R₂;

L₃ is either H or a chemically labile group comprising a heteroatom which forms a chemical linkage to R₂;

each R₂ is, independently, a group comprising a reporter;


R₁ is a substituent (e.g., a reporter or quencher at the terminus of the polyphosphate) that suppresses the template directed polymerase incorporation rate of the nucleoside triphosphate onto the 3' end of an extending oligonucleotide prior to cleavage of L₂-R₂ from the previous incorporation event;

L_2-R_2 prevents the template directed polymerase incorporation of the compound of the formula (I) onto the 3' end of an extending oligonucleotide onto which a compound of the formula (I) has been incorporated;

l is an integer; and

$m = 3l - 1$.

[0008] A compound which has a structure represented by the following formula (II) is also provided:



wherein B , R_1 , L_1 , F , L_2 , R_2 , l and m are defined as set forth above for formula (I).

[0009] A method of sequencing a nucleic acid is also provided which comprises:

(a) hybridizing a primer to a target polynucleotide to form a primer-target duplex, wherein the target polynucleotide is attached to a solid support at the 3' or 5' end of the target polynucleotide;

(b) contacting the primer-target duplex with a polymerase and one or more nucleotide analogs to incorporate a nucleotide analog onto the 3' end of the primer thereby forming an extended primer strand, wherein the incorporated nucleotide analog terminates the polymerase reaction and wherein each of the one or more nucleotide analogs comprises: (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine, uracil and their analogs; (ii) a label attached to the base or analog

thereof via a cleavable linker; (iii) a deoxyribose; and (iv) one or more phosphate groups, wherein the label is unique for the base and wherein the combination of the polyphosphate terminal substituent, the linker and/or the label inhibits the template directed polymerase incorporation of a further nucleotide analog onto the extended primer strand;

(c) washing the surface of the solid support to remove unincorporated nucleotide analogs;

(d) detecting the unique label attached to the just-incorporated nucleotide analog to thereby identify the just-incorporated nucleotide analog;

(e) cleaving the cleavable linker between the just incorporated nucleotide analog and the unique label thereby allowing the incorporation of a further nucleotide analog onto the extended primer strand;

(f) washing the surface of the solid support to remove cleaved compound fragments; and

(e) repeating steps (b), (c), (d), (e) and (f).

[0010] These and other features of the present teachings are set forth herein.

BRIEF DESCRIPTION OF THE DRAWINGS

The skilled artisan will understand that the drawings, described below, are for illustration purposes only. The drawings are not intended to limit the scope of the present teachings in any way. The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0011] FIG. 1 is a schematic illustrating a method for the serial release of a reporter for a dual reporter system during DNA sequencing by synthesis.


[0012] FIGS. 2A and 2B are schematics illustrating the chemical structures of two unnatural DNA substrates having photo-cleavable linkers.

[0013] FIGS. 3A and 3B are schematics illustrating the polymerase incorporation of nucleotide analogs having amino terminal residues (FIG. 3A) and glycolate terminal residues (FIG. 3B) into an extending DNA strand over a template.

[0014] FIG. 4 is a schematic showing the general structure of a reversible terminator.

[0015] FIGS. 5A-5D are schematics illustrating exemplary chemical structures of four reversible terminator bases that have free 3' hydroxyl groups.

[0016] FIG. 6 is a schematic illustrating the use of a reversible terminator having a free 3'-hydroxyl group showing cleavage of the reporter from the incorporated reversible terminator on the end of the strand followed by incorporation of another reversible terminator to the end of the strand wherein:



[0017] FIG. 7 is a schematic showing the structure of a first reversible terminator having a silver ion cleavable linker and illustrating the chemistry involved with silver ion chemical cleavage.

[0018] FIG. 8 is a schematic showing the structure of a second reversible terminator having a silver ion cleavable linker and illustrating the chemistry involved with silver ion chemical cleavage.

[0019] FIGS. 9A-9D are schematics illustrating the structure of reversible terminators having linkers between the base and the reporter that can be cleaved by a basic compound such as ammonia.

[0020] FIGS. 10A-10D are schematics illustrating the structure of silver ion cleavable linkers that can be cleaved in a single silver ion step or in multiple steps comprising silver ions to yield hydroxyl or amino groups at the terminal end of the linker residue.

[0021] FIG. 11 is a schematic illustrating the use of silver ion cleavable groups which leave a phosphate terminal group on the residue.

[0022] FIGS. 12A and 12B are electropherograms showing polymerase extension over an (AAG)₁₄ [SEQ ID NO: 1] template using a dUTP analog having residues with methyl terminal groups on the base (FIG. 12A) and a dUTP analog having residues with amino terminal groups on the base (FIG. 12B).

[0023] FIGS. 13A, 13B and 13C are electropherograms showing polymerase extension over an (AAG)₁₄ [SEQ ID NO: 1] template with natural dCTP/dTTP (FIG. 13A), a dNTP analog having residues with a methyl terminal group on the base (FIG. 13B), and a dNTP analog having residues with a hydroxyl terminal group on the base (FIG. 13C), wherein N is U or C.

[0024] FIG. 14 is a schematic illustrating the polymerase directed addition of a nucleotide analog having a γ -phosphate substituent (R₁) and a substituent on the base to the 3' end of a nucleic acid over a template.

[0025] FIG. 15 is a schematic illustrating variations in the γ -phosphate substituent (R_1). When the γ -phosphate substituent (R_1) is a hydrocarbon group, a second nucleotide analog cannot be added to the 3' end of the nucleic acid until the substituent is removed from the base via cleavage and when R_1 is H, extension occurs at the 3' end of the nucleic acid.

[0026] FIGS. 16A-16D are schematics showing the chemical structures of four different non-cleavable nucleotide analogs, dATP-L-Cy5, dCTP-L-Cy3, Benz-dATP-L-Cy5 and HC-dATP-L-Cy5, respectively, wherein the dATP-L-Cy5 and dCTP-L-Cy3 analogs do not have a γ -phosphate substituent and wherein the Benz-dATP-L-Cy5 analog shown in FIG. 16C has a benzyl group as a γ -phosphate substituent and the HC-dATP-L-Cy5 analog shown in FIG. 16D has a hydrocarbon group (i.e., HC) as a γ -phosphate substituent.

[0027] FIGS. 17A and 17B are electropherograms illustrating the termination effect of a γ -phosphate benzyl substituent on the nucleotide analog.

[0028] FIGS. 18A and 18B are electropherograms illustrating that a nucleotide analog which does not have a γ -phosphate substituent (e.g., the nucleotide analog of FIGS. 16A or 16B) can be incorporated after a nucleotide analog having a γ -phosphate benzyl substituent (e.g., the nucleotide analog of FIGS. 16C or 16D).

[0029] FIG. 19 illustrates the use of reversible terminators having silver ion cleavable linkers between the dye and the base wherein terminator activity is selectively controlled by the presence of a γ -phosphate substituent (R) and the Linker group (L) linking the base to the dye.

[0030] FIGS. 20A and 20B are electropherograms showing incorporation data for a 31 p(dA) template (i.e., 31 contiguous dA's) using Terminator II polymerase with dTTP (FIG. 20A) and a dUTP nucleotide analog having a propargyl alcohol residue on the base (FIG. 20B).

[0031] FIGS. 21A-21D are electropherograms showing the termination properties of γ -phosphate substituted dUTP analogs having an O-propargyl-S-substituent at the 5 position.

[0032] FIGS. 22A-22D are electropherograms showing the mis-incorporation properties of γ -phosphate substituted dUTP analogs having an O-propargyl-S-substituent at the 5 position.

[0033] FIGS. 23A-23C are electropherograms and a schematic showing the cleavage reactions needed to regenerate the 3'-hydroxyl for the next termination event wherein FIG. 23A shows the incorporation of dU onto a primer-target duplex, FIG. 23B shows a nearly quantitative cleavage of the linker with silver ions to the phosphate and FIG. 23C shows the loss of the phosphate group from the fragment by treatment with Calf Intestine Phosphatase.

[0034] FIG. 24 is a schematic illustrating the synthesis of a propargyl ester of phosphorothiolate linker (8).

[0035] FIG. 25 is a schematic illustrating the synthesis of dU 5'-monophosphate (10).

[0036] FIG. 26 is a schematic illustrating the synthesis of dC 5'-monophosphate (12).

[0037] FIG. 27 is a schematic illustrating the synthesis of dA 5'-monophosphate (14).

[0038] FIG. 28 is a schematic illustrating the synthesis of dG 5'-monophosphate (16).

[0039] FIG. 29 is a schematic illustrating the synthesis of methylpyrophosphate (19).

[0040] FIG. 30 is a schematic illustrating the synthesis of benzylpyrophosphate (21).

[0041] FIG. 31 is a schematic illustrating the synthesis of 2-(N-(3-methylimidazolium))-ethyl pyrophosphate (25).

[0042] FIG. 32 is a schematic illustrating the synthesis of γ -methyl-dUTP (26).

[0043] FIG. 33 is a schematic illustrating the synthesis of γ -benzyl-dATP (27).

[0044] FIG. 34 is a schematic illustrating the synthesis of γ -(2-(N-(3-methylimidazolium))-ethyl)-dCTP (28).

[0045] FIG. 35 is a schematic illustrating the synthesis of γ -(2-(N-(3-methylimidazolium))-ethyl)-dGTP (29).

[0046] FIG. 36 are electropherograms showing the termination and mis-incorporation properties of γ -benzyl-dATP.

[0047] FIG. 37 are electropherograms showing the termination and mis-incorporation properties of γ -imidazolium-dCTP.

[0048] FIG. 38 are electropherograms showing the termination properties of γ -imidazolium-dCTP at various substrate concentrations.

[0049] FIG. 39 are electropherograms showing the termination and mis-incorporation properties of γ -imidazolium-dGTP.

[0050] FIG. 40 are electropherograms showing the termination properties of γ -imidazolium-dGTP at various substrate concentrations.

DESCRIPTION OF THE VARIOUS EMBODIMENTS

For the purposes of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural

and vice versa. In the event that any definition set forth below conflicts with the usage of that word in any other document, including any document incorporated herein by reference, the definition set forth below shall always control for purposes of interpreting this specification and its associated claims unless a contrary meaning is clearly intended (for example in interpreting the document where the term is originally used). The use of "or" herein means "and/or" unless stated otherwise or where the use of "and/or" is clearly inappropriate. The use of "a" herein means "one or more" unless stated otherwise or where the use of "one or more" is clearly inappropriate. The use of "comprise," "comprises," "comprising," "include," "includes," and "including" are interchangeable and not intended to be limiting. Furthermore, where the description of one or more embodiments uses the term "comprising," those skilled in the art would understand that, in some specific instances, the embodiment or embodiments can be alternatively described using the language "consisting essentially of" and/or "consisting of." It should also be understood that in some embodiments the order of steps or order for performing certain actions is immaterial so long as the present teachings remain operable. Moreover, in some embodiments two or more steps or actions can be conducted simultaneously.

[0051] As used herein, the term "nucleoside" includes 2'-deoxy nucleosides and 2'-hydroxyl nucleosides. The term "analogs" in reference to nucleosides includes synthetic nucleosides having modified base moieties and/or modified sugar moieties. Such analogs include synthetic nucleosides designed to enhance binding properties, reduce degeneracy, increase specificity, and the like. Such analogs also include nucleosides having residues attached to the base which do not occur in the natural nucleoside.

[0052] As used herein, the term "heteroatom" means an atom other than H or C.

[0053] As used herein, the phrase "terminal group" refers to the functional group at the terminal position of a moiety. For example, cleavage of the linker connecting the reporter (e.g., Dye) to the base of a nucleotide analog can leave a residue having a

terminal group attached to the base. The terminal group remaining after cleavage is dependent upon the site of the cleavage reaction. The terminal group includes at least one atom other than H. Exemplary and non-limiting examples of terminal groups include hydroxyl and sulfhydryl groups.

[0054] As used herein, the phrase “nucleotide analog” refers to a chemical compound that is structurally and functionally similar to a nucleotide and which can be recognized by a polymerase as a substrate. Nucleotide analogs include nucleotides comprising labels attached to the nucleotide via a cleavable linker and nucleotides in which the -OH group at the 3' position of the deoxyribose is capped (e.g., with a chemical moiety such as $-\text{CH}_2\text{OCH}_3$ or $-\text{CH}_2\text{CH}=\text{CH}_2$). Nucleotide analogs of this type are disclosed in U.S. Patent No. 6,664,079 B2.

[0055] As used herein, the phrase “oligonucleotide” refers to a linear oligomer of nucleosides or analogs thereof, including deoxyribonucleosides, ribonucleosides and the like. Oligonucleotides can range in size from a few monomeric units (e.g., 3 to 4 units) to several hundred monomeric units.

[0056] As used herein, the term “label” and the term “reporter” are used interchangeably and refer to a detectable moiety (i.e., a moiety which emits a detectable signal). The moiety can be a fluorescent moiety.

[0057] As used herein, the term “quencher” refers to a moiety which reduces the signal emitted by the label or reporter when in close proximity thereto (e.g., when attached to the same compound as the label). If the label is a fluorescent moiety, the quencher can be a moiety which reduces fluorescent emissions via a fluorescence energy transfer (such as FRET) mechanism. FRET occurs between a donor fluorophore (i.e., the fluorescent label, e.g., a reporter in the FRET system which provides a detectable signal

in the absence of FRET, when for example the quencher is removed, and functions as an energy transfer donor in the presence of FRET, when for example the quencher is present) and an acceptor (e.g., a quencher which in FRET functions as a non-fluorescent energy transfer acceptor) when the absorption spectrum of the quencher molecule overlaps with the emission spectrum of the donor fluorophore or when the two molecules are in close proximity. Other mechanisms of fluorescence quenching are also known and include, but are not limited to, collisional and charge transfer quenching.

[0058] As used herein, the phrase “unique label” refers to a detectable moiety that can be distinguished from other detectable moieties in the sample. For example, each of the nucleotide analogs of T, G, A and C can have a unique label. The presence of the signal associated with a given label is therefore indicative of the presence of the nucleotide analog to which it is attached. The use of unique labels therefore allows for the determination of the nucleotide analog added to the end of the extending nucleic acid during sequencing by synthesis.

[0059] As used herein, the phrase “permanent linkage” refers to a linkage that is not cleaved.

[0060] As used herein, the phrase “transient linkage” refers to a linkage that can be cleaved (e.g., a chemically labile linkage, a photo-cleavable linkage).

[0061] DNA sequencing via “sequencing by synthesis” involves the interrogation of each base on a target by primer/polymerase based synthesis of the target’s complement in a stepwise manner. This technique involves the serial incorporation of a “reversible terminator” which contains a reporter and which blocks synthesis once the terminator is incorporated. The terminator contains a reporter specific for the base to which it is


attached. The reporter can be a fluorescent reporter and is a detectable moiety. Termination can be reversed by the removal of a blocking group (e.g., on the 3' hydroxyl of the incorporated reversible terminator) and further extension can then be sustained. The reporter can be removed after interrogation and prior to further extension, or the reporter and blocking groups can be removed simultaneously.

[0062] Reporters that signify incorporation events can reside on the γ -position of the triphosphate where the reporter can be removed from the interrogation volume by diffusion of the resulting pyrophosphate from the extension product. Alternatively, reporters can be attached to the base. When attached to the base, the reporter must be removed in a separate step from the extension product prior to the next incorporation event in order to prevent the reporter dyes from quenching each other and to ensure that each signal can be unambiguously identified with an incorporating base. Further information is provided in Mitra, R.D. et al., "Fluorescent in situ sequencing on polymerase colonies" *Analytical Biochemistry*, vol. 320(1), pp.55-65 (2003), incorporated by reference herein in its entirety. Several different approaches have been attempted for single molecule sequencing. For example, the use of a "nanopore" (i.e., a nanometer scale pore in an insulating membrane) is disclosed in Nakane et al., *Condens. Matter* 15 (2003) R1365-R1393. In addition, the use of a zeromode wave guide is disclosed in Levene et al., *Science* 299 (2003), pp. 682-686. Also, the simultaneous stepwise extension of many fragments with a dye labeled nucleotide on a flat surface is disclosed in Braslavsky et al., *PNAS* 100 (2003), pp. 3960-3964. Additional nucleic acid sequencing and single-molecule detection schemes are described in U.S. Pat. Application Serial No. 11/345,979 by McKernan et al., filed February 1, 2006 and U.S. Pat. Application Serial No. 11/737,308 by K.J. McKernan et al., filed April 19, 2007, incorporated herein by reference in its entirety for all purposes.

[0063] The addition of a nucleotide analog having an organic substituent (e.g., a fluorescent reporter) R_1 attached to the γ -position of the triphosphate and a fluorescent reporter R_2 attached to the base is shown in FIG. 1. As shown in FIG. 1, the nucleotide analog is added to an extending DNA strand resulting in the removal of the substituent R_1 . After the nucleotide has been added to the extending DNA strand, the linker L_2 and fluorescent reporter R_2 can be removed via cleavage of the linkage connecting R_2 to the base thereby allowing for a further incorporation event.

[0064] When the reporter is attached to the base, its removal during sequencing can yield a product that is not the same structure as the natural deoxynucleoside triphosphate (dNTP) substrate due, for example, to the need for linkers (e.g., L_2 and L_3 in FIG. 1) and functional groups (e.g., F in FIG. 1) that enable binding and releasing of the reporter from the base. Moreover, once the moiety is cleaved, a residue from the linker can remain attached to the base which is then incorporated into the extending double stranded DNA. Reversible terminators having residues with terminal amino groups on the base after cleavage of the reporter are disclosed in Ju et al., "Four Color DNA Sequencing by Synthesis Using Cleavable Fluorescent Nucleotide reversible Terminators," PNAS, vol. 35 U.S.C. §103(a), No. 52, pp. 19635-19640 (December 26, 2006).

[0065] As set forth above, the reporter can be attached to the base via a cleavable linker. According to some embodiments, the linker connecting the reporter to the base can be a photo-cleavable linker. Polymerase substrates wherein the reporter is attached to the base via a photo-cleavable linker are shown in FIGS. 2A and 2B. In FIGS. 2A and 2B, F is N or O, L_1 is propargyl (i.e., $-C-C\equiv C-$) and L_2 is a photo-cleavable linker moiety represented by the structure:



wherein R_2 is a fluorescent reporter.


[0066] In FIG. 2A, the terminal functional group on the residue remaining after cleavage of the linkage between the reporter and the base is an amino group. When such a substrate is incorporated into an extending DNA strand (e.g., in a sequencing by synthesis method), the extending DNA would include residues having terminal amino groups as illustrated in extending DNA in FIG. 3A. As can be seen from FIG. 3A, this structure comprises amino group terminated residues on each of the bases in the extended nucleic acid strand.

[0067] Based on experiments that are described in detail below, it was discovered that certain residues remaining on the base after cleavage are more compatible with extension over the resulting double-stranded DNA than other residues. In particular, it has been discovered that linker residues in unnatural bases in the extending strand comprising terminal amino groups can severely retard incorporation of the triphosphate substrates after 8 - 10 incorporation events. However, when the linker residues in the unnatural bases in the extending strand are terminated with a methyl or hydroxyl-groups (as shown in extending DNA in FIG. 3B), incorporation can be sustained for at least 50 bases.

[0068] Under certain conditions (e.g., with variations of linker structure and polymerase), triphosphate nucleosides containing a free 3' hydroxyl and a linker-reporter extending off of the base will incorporate once but will fail to incorporate a second time until the linkage coming off of the base is cleaved to remove the reporter.

For example, reversible terminators having free 3'-hydroxyl groups are disclosed in Wu et al., "Termination of DNA Synthesis by N6-alkylated, not 3'-O-alkylated, photo-cleavable 2'-Deoxyadenosine Triphosphates", *Nucleic Acids Research* (2007), 35(19), 6339-6349) and Wu et al., 3'-O-modified nucleotides as reversible terminators for pyrosequencing, *Proceedings of the National Academy of Sciences of the United States of America* (2007), 104(42), 16462-16467. These reversible terminators have 2-nitrobenzyl groups on the base which can be removed via UV light to restore the natural nucleotide and allow incorporation into the extending DNA strand. However, the terminating effects of the un-cleaved extended substrate on the ability of the next dNTP to incorporate are very sensitive to the structure of the linker on the base, and the polymerase.

[0069] Accordingly, a compound represented by the following formula (I) is provided:



wherein:

B is a base selected from the group consisting of adenine, guanine, cytosine, uracil and thymine or their respective analogs;

L₁ is a group that forms a linkage to the base B and F;

F is a heteroatom that forms a linkage between L₁ and L₂;

L₂ is a chemically labile group with respect to F and forms a chemical linkage to reporter R₂;

L_3 is either H or a chemically labile group comprising a heteroatom which forms a chemical linkage to reporter R_2 ;

each R_2 is, independently, a group comprising a reporter, wherein the combination of L_2 and R_2 prevents the template directed polymerase incorporation of the compound onto the 3' end of an extending oligonucleotide onto which a compound of the formula (I) has been incorporated;

R_1 is a neutral substituent, selected from substituted or un-substituted alkyl, substituted or unsubstituted aromatic, substituted or un-substituted heterocycle, substituted or unsubstituted aromatic heterocycle substituents, or (anionic or cationic forms thereof, where the substituent suppresses the template directed polymerase incorporation rate of the nucleoside triphosphate onto the 3' end of an extending oligonucleotide prior to the cleavage of L_2 - R_2 from the previous incorporation event;

l is an integer; and


$m = 3l - 1$.

[0070] According to some embodiments, cleavage of the chemically labile group L_2 leaves a linker residue moiety having a terminal group attached to the base. According to some embodiments, the terminal group of the residue is not an amino group. According to some embodiments, the terminal group of the residue is an hydroxyl group. According to some embodiments, l is 2, 3, or 4.

[0071] As set forth above, L_3 can be H (i.e., the compound can have a free or unblocked 3' hydroxyl group). In contrast to the reversible terminators where the 3'-hydroxyl is blocked and must be removed prior to the next incorporation event, reversible terminators with unblocked 3'-hydroxyl groups do not require a separate unblocking step. The substrates with blocked 3'-hydroxyl groups can also be poor

substrates for polymerases and the rates of incorporation can be very slow, requiring elevated substrate concentration and long reaction times.

[0072] Accordingly, a compound is also provided which has a structure represented by the following formula (II):



wherein B, R₁, L₁, F, L₂, R₂, l and m are defined as set forth above for formula (I).

[0073] For these compounds, the 3'-hydroxyl is always free and the selectivity of the "termination" (i.e., the suppression of incorporation of the next base until the linker L₂-R₂ is cleaved) can be optimized by altering structures at L₂ and R₁.

[0074] In the compounds of formulae (I) and (II) above: F can be a linkage which results in an hydroxyl terminating residue upon cleavage; L₂ and L₃ can be a chemically cleavable group such as a thioacetal, a thioester, or an ester; L₂-R₂ is a linker-reporter combination wherein the presence of the linker and/or reporter on the incorporated base in the extending strand suppresses the polymerase catalyzed incorporation of the next base which contains a similar linker-reporter L₂-R₂; and R₁ is a group bound to the γ-phosphate of a triphosphate or the δ-phosphate of a tetraphosphate which acts to

suppress the rate of incorporation of the next nucleotide when the previous nucleotide incorporated still contains L_2-R_2 .

[0075] As set forth above, R_1 is a group that suppresses the template directed polymerase incorporation rate of the nucleoside triphosphate onto the 3' end of an extending oligonucleotide prior to the cleavage of L_2-R_2 from the previous incorporation event. According to some embodiments, R_1 can be a substituted or unsubstituted hydrocarbon group. Non limiting examples of substituted or unsubstituted hydrocarbon groups include, (i) substituted or un-substituted alkyls, substituted or unsubstituted aromatics, substituted or un-substituted heterocycles, substituted or unsubstituted aromatic heterocycles, or (ii) neutral, anionic, or cationic forms of (i),.

[0076] The structures of four exemplary reversible terminator bases having free 3' hydroxyl groups are shown in FIGS. 5A-5D. The variables in FIGS. 5A-5D are defined as follows: L_2 is a chemically labile linking group such as $C(O)S-$, $C(O)O-$, $CH(SMe)phenyl-$, $[RO]_2P(O)S-$; R_2 is a group containing a reporter moiety that in combination with L_2 suppresses the incorporation rate of the nucleoside triphosphate during polymerase dependent template directed DNA synthesis when the preceding nucleotide contains a group L_2-R_2 with the same or similar structure, but allows incorporation when the group on the preceding nucleotide has been cleaved at L_2 , resulting in cleavage residue F; and R_1 is an organic substituent selected from (i) substituted or un-substituted alkyls such as methyl, propargyl or benzyl, substituted or unsubstituted aromatics such as phenyl, methoxyphenyl, or naphthyl, substituted or unsubstituted heterocycles such as tetrahydropyrrole or piperazine, substituted or unsubstituted aromatic heterocycles such as quinolyl, methylimidazolyl, pyridyl,

imidazolyl, or benzoimidazolyl or (ii) neutral, anionic (e.g., benzenesulfonate), or cationic (e.g., trimethylammonium, phenyl or imidazolium) forms of (i) .

[0077] An example of the use of a reversible terminator having a free 3'-hydroxyl group is shown in FIG. 6. In FIG. 6, the cleavable group L_2 is thioacetal, the linker residue L_1-F from the cleavage is $-C\equiv C-CH_2-NH-C(O)-CH_2-OH$, and the moiety which suppresses the incorporation of the next nucleotide is the substituted aromatic structure. The thioacetal group shown in FIG. 6 is cleavable by a silver ion.

[0078] FIG. 7 shows the structure of a reversible terminator having a free 3' hydroxyl group wherein the cleavable group linking the reporter to the base is a thiocarbonate group. The thiocarbonate group is also cleavable by a silver ion. FIG. 7 also illustrates the chemistry involved in the silver ion chemical cleavage of the substrate after incorporation into a DNA strand.

[0079] FIG. 8 shows the structure of a polymerase substrate wherein the cleavable group L_2 is a thioacetal group. The thioacetal group is also cleavable by a silver ion. FIG. 8 also illustrates the chemistry involved in the silver ion chemical cleavage of the substrate after incorporation into a DNA strand.

[0080] FIGS. 9A-9D illustrate the structures of polymerase substrates having different cleavable linkers between the base and the reporter that can be cleaved by a basic compound (e.g., ammonia) where $F = \text{oxygen atom}$ and $L_1 = \text{propargyl}$.

[0081] FIGS. 10A-10D are schematics illustrating the structure of silver ion cleavable linkers with dye labeling capabilities that can be cleaved to yield hydroxyl or amine groups at the terminal end of the linker residue.

[0082] FIG. 11 is a schematic illustrating the use of silver ion cleavable groups which leave a phosphate terminal group on the residue. In the structure shown in FIG. 11, the benzene ring to which the "DYE" is attached can be unsubstituted (as shown) or substituted (not shown).

[0083] The label that is attached to the nucleotide analogue can be a fluorescent moiety. The fluorescent moiety can be a moiety selected from the group consisting of fluorescein, rhodamine, cyanine, and/or bodipy dyes.

[0084] According to some embodiments, the unique label is attached through a cleavable linker to a 5-position of cytosine or thymine or to a 7-position of deaza-adenine or deaza-guanine. The unique label can also be attached through a cleavable linker to another position in the nucleotide analogue as long as the attachment of the label is stable during the polymerase reaction and the nucleotide analog can be recognized by polymerase as a substrate.

[0085] The nucleotide analogues disclosed herein can be used for detection of single nucleotide polymorphisms, genetic mutation analysis, methylation detection, serial analysis of gene expression, gene expression analysis, identification in forensics, genetic disease association studies, DNA sequencing, RNA sequencing, genomic sequencing, translational analysis, and transcriptional analysis.

[0086] Accordingly, a method of sequencing a nucleic acid is also provided which comprises:

(a) hybridizing a primer to a target polynucleotide to form a primer-target duplex, wherein the target polynucleotide is attached to a solid support at the 3' or 5' end;

(b) contacting the primer-target duplex with a polymerase and one or more nucleotide analogs to incorporate a nucleotide analog onto the 3' end of the primer thereby forming an extended primer strand, wherein the incorporated nucleotide analog terminates the polymerase reaction and wherein each of the one or more nucleotide analogs comprises: (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine, uracil and their analogs; (ii) a label attached to the base or analog thereof via a cleavable linker; (iii) a deoxyribose; (iv) three or more phosphate groups, wherein the label is unique for the base and wherein the linker and/or the label inhibits the template directed polymerase incorporation of a further nucleotide analog onto the extended primer strand; and (v) an organic moiety on the terminus of the polyphosphate, wherein the presence of the moiety inhibits incorporation of the next nucleotide analog prior to cleavage of the organic moiety from a previous incorporation of (ii) but allows the incorporation of the next nucleotide analog after cleavage of the organic moiety from a previous incorporation of (ii).

(c) washing the surface of the solid support to remove unincorporated nucleotide analogs;

(d) detecting the unique label attached to the just-incorporated nucleotide analog to thereby identify the just-incorporated nucleotide analog;

(e) cleaving the cleavable linker between the just incorporated nucleotide analog and the unique label thereby allowing the incorporation of a further nucleotide analog onto the extended primer strand;

(f) washing the surface of the solid support to remove cleaved compound fragments; and

(e) repeating steps (b), (c), (d), (e) and (f).

[0087] Each of the one or more nucleotide analogs can have a structure represented by formula (I) or formula (II) above. The one or more nucleotide analogs may comprise: A first nucleotide analog wherein B is adenine having a first label; a second nucleotide analog wherein B is guanine having a second label; a third nucleotide analog wherein B is cytosine having a third label; and a fourth nucleotide analog wherein B is thymine having a fourth label. The labels may be fluorescent labels. One of skill in the art would understand the use of uracil as a fourth label for RNA sequencing and analyses.

[0088] Non-limiting examples of the DNA polymerase include Thermo Sequenase, Taq FS DNA polymerase, T7 DNA polymerase, Therminator, Therminator II, and Vent (exo-) DNA polymerase. The structure of the nucleotide analog can be optimized for the polymerase used for extension. Structure optimization can include the structure and selection of substituents for R_1 and L_2 and in the selection of the "Dye" (detection moiety).

[0089] The fluorescence emission from each specific dye can be detected using a fluorimeter that is equipped with an accessory to detect fluorescence from a solid surface. For large scale evaluation, a multi-color scanning system capable of detecting multiple different fluorescent dyes (e.g., 500 nm-700 nm, 400 nm-800 nm and so on) can be used.


[0090] The nucleotide analogs described herein can be used in DNA and RNA sequencing strategies that utilize single molecule detection, real time DNA and RNA sequencing, or any other technique where the DNA or RNA sequence is determined serially by interrogation of each incorporation event with a base labeled reporter, followed by chemical, thermal, enzymatic or other physical cleavage of the reporter prior to the next incorporation event.

[0091] The methods and compounds described herein can be used to sequence amplified targets as well as single molecules.

EXAMPLES

Aspects of the present teachings may be further understood in light of the following examples, which should not be construed as limiting the scope of the present teachings in any way. Although the examples are for DNA nucleotides, RNA nucleotides are also envisioned as would be understood to one of skill in the art.

[0092] In order to determine if a polymerase would continue to extend an unnatural DNA (i.e., a DNA including moieties not present in natural DNA) comprising residues having amino groups, an experiment was designed using aminopropargyl-dUTP (deoxyuridine triphosphate) and dCTP (deoxycytidine triphosphate) which yields extended DNA having residues with terminal amino functional groups on the incorporated dUTP moieties. The dUTP used is represented by the formula:




The experiment was conducted using an FAM (i.e., 6-carboxyfluorescein) labeled primer over an (AAG)₁₄ [SEQ ID NO: 1] template.

[0093] As illustrated in FIG. 12B, electrophoresis of the product shows poor extension as illustrated by the multiple FAM peaks (dark peaks, light peaks are a size standard) in the electropherogram trace which demonstrate failure to sustain the synthesis. These results indicate no extension beyond about 14 bases of the 42 base target template.


[0094] This contrasts with the use of methylpropynyl dUTP and dCTP over the same template which shows extension to a single product as illustrated in the electropherogram of FIG. 12A. It should be noted that the size differences in the electropherograms of FIG. 12A and FIG. 12B results from the large apparent size of the

amino fragments due to low mobilities imparted to the fragments by the positively charged amino groups

[0095] While not wishing to be bound by theory, it appears that the amino-group in the residue attached to the incorporating base interferes with the polymerase enzyme activity. A neutral substrate was therefore designed having a structure as set forth below and in FIG. 2B:




wherein F is O, L₁ is propargylamide (i.e., -C-C≡C-C-NH-C(O)-C-), and L₂ is a moiety represented by the structure:



wherein R₂ is a fluorescent reporter. This structure corresponds to the general structure of FIG. 1 wherein L₁-F is glycolate. This structure therefore yields a glycolate linkage instead of an amino-linkage upon photo-chemical cleavage.

[0096] To conduct these experiments, a dUTP substrate having the following moiety attached to the 5-position of the base was synthesized.



The structure of the dUTP analog used in this experiment is set forth in FIG. 5D. This nucleotide analog therefore has an hydroxyl terminal moiety attached to the base.

[0097] These substrates were tested against the same template/primer system used in the experiments shown in FIGS. 12A and 12B {i.e., Klenow enzyme at 37 °C for 1 minute over an (AAG)₁₄ [SEQ ID NO: 1] template}. The concentration of the nucleotides for this experiment was 5 μM. The results of this experiment are summarized in the electropherogram of FIG. 13C.

[0098] Similar experiments were conducted over the same template for natural dCTP/dTTP, with results shown in the electropherogram of FIG. 13A, and the methylpropynyl analogs of these substrates, with results shown in the electropherogram of FIG. 13B.

[0099] The electropherogram of FIG. 13C shows excellent synthesis of the extension product for the nucleotide analogs having an hydroxyl terminal moiety attached to the base. Moreover, the electropherograms of FIGS. 13A, 13B and 13C show that the extension in each case goes to completion with similar efficiencies. Therefore, hydroxyl terminal residues on the base of the nucleotide analogs do not appear to interfere with polymerase directed extension of the nucleic acid strand over a template.

[0100] The use of a glycolate linker enables photo-chemical cleavage and provides a practical synthesis route to these compounds. The functionalized substrate is active to photo-chemical cleavage and the resulting product has an hydroxyl terminal residue which does not interfere with enzymatic synthesis of DNA on the extending strand.

[0101] Additional experiments were conducted to determine the effects of a γ -phosphate substituent (i.e., R_1) and a substituent on the base (i.e., $-L_1-F-L_2-R_2$) on the termination of nucleotide analogs having a free 3' hydroxyl group.

[0102] FIGS. 14 and 15 are schematics illustrating the polymerase directed addition of a nucleotide analog having a γ -phosphate substituent (R_1) and a -linker- Dye (L_2-R_2) substituent on the base to the 3' end of a nucleic acid over a template, where - L_2 - represents any combination of functional linkages including, but not limited to, ester, amide and benzylic ether linkages between the linker and Dye that will maintain enzyme activity and enable directed cleavage of the dye from the linker after enzymatic incorporation of the nucleotide. FIG. 14 shows a first nucleotide analog being incorporated into the nucleic acid. As illustrated in FIG. 15, when R_1 is H, a second nucleotide analog can be added to the 3' end of the nucleic acid resulting in primer extension. However, when R_1 is a hydrocarbon group (e.g., methyl, propargyl or benzyl), the second nucleotide analog is not added to the 3' end of the nucleic acid until the $-L_2-R_2$ substituent is cleaved from the base. As shown in FIG. 15, R_1 can be H or R_1 can be a hydrocarbon or a heteroatom substituted hydrocarbon.

[0103] FIGS. 16A-16D are schematics showing the chemical structures of four different non-cleavable nucleotide analogs, dATP-L-Cy5, dCTP-L-Cy3, Benz-dATP-L-Cy5, and HC-dATP-L-Cy5 respectively. The dATP-L-Cy5 (FIG. 16A) and dCTP-L-Cy3 (FIG. 16B) analogs do not have a γ -phosphate substituent (i.e., R_1 is H) whereas the Benz-dATP-L-Cy5 analog shown in FIG. 16C has a benzyl group as a γ -phosphate substituent and the HC-dATP-L-Cy5 analog shown in FIG. 16D has a hydrocarbon (HC) group as a γ -phosphate substituent. The hydrocarbon group can be a substituted or unsubstituted alkyl or aromatic group, and the substituents can be heteroatoms that

result in neutral, cationic or anionic groups. The R substituent on the phenyl ring can be hydrogen, a hydrocarbon, a cationic group or an anionic group.

[0104] FIGS. 17A and 17B are electropherograms illustrating the termination effect of a γ -phosphate benzyl substituent on the nucleotide analog. The template used in this experiment includes the following sequence:

3' ACATTTGCTGCCGGTCAGTGT . . . 5' [SEQ ID NO: 2]

wherein the underlined portion of the sequence indicates where the dye-labeled primer hybridized. The electropherogram of FIG. 17A shows the incorporation of dATP-L-Cy5 (FIG. 16A) after the incorporation of dCTP-L-Cy3 (FIG. 16B). In particular, the signals from both Cy-3 and Cy-5 can be seen in the electropherogram of FIG. 17A. In FIG. 17A, a relatively small peak can be observed for the first dC incorporation, a big peak can be observed for the unsubstituted dA incorporation, and a third peak can be observed for an additional dC incorporation. The electropherogram of FIG. 17B shows that Benz-dATP-L-Cy5 (FIG. 16C) is not incorporated after the incorporation of dCTP-L-Cy3 (FIG. 16B). In particular, only the signal for Cy-3 can be seen in the electropherogram of FIG. 17B.

[0105] FIGS. 18A and 18B are electropherograms illustrating that a nucleotide analog which does not have a γ -phosphate substituent can be incorporated after a nucleotide analog having a γ -phosphate benzyl substituent (i.e., the nucleotide analog of FIG. 16C). The template used in this experiment includes the following sequence:

3' ACATTTGCTGCCGGTCATGTC . . . 5' [SEQ ID NO: 3]

wherein the underlined portion of the sequence indicates where the dye-labeled primer hybridized. Compared to the template used in the experiments of FIGS. 17A and 17B, for this template the first two bases on the template 5' of the primer have been switched


to verify that the Benz-dATP-L-Cy5 was in fact a substrate for the polymerase. The electropherogram of FIG. 18A shows the incorporation of dCTP-L-Cy3 (FIG. 16B) after the incorporation of dATP-L-Cy5 (FIG. 16A). In particular, the signals from both Cy-3 and Cy-5 can be seen in the electropherogram of FIG. 18A. The electropherogram of FIG. 18B shows that dCTP-L-Cy3 (FIG. 16B) is incorporated after the incorporation of Benz-dATP-L-Cy5 (FIG. 16C). In particular, the signals from both Cy-3 and Cy-5 can be seen in the electropherogram of FIG. 18B. As can be seen from FIG. 18B, the Benz-dATP-L-Cy5 is readily incorporated followed by the incorporation of dCTP-L-Cy3. At this point, incorporation of additional nucleotide analogs stops due to the presence of the linker from the incorporated dCTP-L-Cy3 in the extended primer.

[0106] FIG. 19 is a schematic illustrating the use of reversible terminators having silver ion cleavable linkers between the dye and the base wherein terminator activity is selectively controlled by the presence of a γ -phosphate substituent (R_1) and the Linker group (L) linking the base of the nucleotide analog to the dye. As shown in FIG. 19, silver ion cleavage yields a linker residue on the base having a phosphate terminal group and phosphatase cleavage subsequently yields a propargyl alcohol residue on the base. It has been found that the propargyl residue remaining on the base after cleavage does not interfere with further extension of the nucleic acid.

[0107] FIGS. 20A and 20B are electropherograms showing incorporation data for a 31 p(dA) template (i.e., 31 contiguous dA's) using Therminator II polymerase with dTTP (FIG. 20A) and a dUTP nucleotide analog having a propargyl alcohol residue on the base (FIG. 20B). FIGS. 20A and 20B demonstrate the ability of polymerases to incorporate nucleotide analogs having a propargyl alcohol residue on the base. In

particular, more than 31 peaks are observed in both FIG. 20A for dTTP and in FIG. 20B for the dUTP nucleotide analog having a propargyl alcohol residue on the base indicating incorporation over the length of the template.

[0108] FIGS. 21A-21D are electropherograms showing the termination properties of γ -phosphate substituted dUTP analogs having an O-propargyl-S-substituent at the 5 position over a p(dA) template. The nucleotide analog used in these experiments had a general structure as set forth below:



wherein R_1 is a methyl group. The substrate concentration was 1 μ M. FIG. 21A is an electropherogram for the primer. FIGS. 21B-D are the electropherograms after 10, 30 and 60 minutes of extension, respectively. As can be seen from FIGS. 21A-21D, the presence of the γ -phosphate substituent and the O-propargyl-S-substituent at the 5 position prevents the extension of the nucleotide analog over the p(dA) template. In particular, as can be seen from FIG. 21B, extension to the first p(dA) is almost complete after 10 minutes. However, even after one hour (FIG. 21D), there has been no observable incorporation of the nucleotide analog onto the second p(dA).

[0109] FIGS. 22A-22D are electropherograms showing the mis-incorporation properties of γ -phosphate substituted dUTP analogs having an O-propargyl-S-substituent at the 5 position and a benzyl group as a γ -phosphate substituent. The nucleotide analog used in these experiments had the same general structure as set forth above in the description of FIGS. 21A-21D. For these experiments, all reactions were

conducted for 10 minutes at a substrate concentration of 1 μM using Mg^{2+} . Two templates were used:

5' (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTAAACTGGCCGTCGTTTTACA 3'

[SEQ ID NO: 4]

which is referred to as the AA template and

5' (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTANACTGGCCGTCGTTTTACA 3'

[SEQ ID NO: 5]

wherein N can be G, C or T, which is referred to as the NA template (i.e., the GA, CA or TA templates). The primer used was:

5' -(6-FAM)TGTAACGACGGCCAGT 3' [SEQ ID NO: 6].

FIG. 22A is the electropherogram for the primer. As can be seen from FIGS. 22B-D, the γ -phosphate substituted dUTP analog having an O-propargyl-S-substituent at the 5 position is incorporated into the AA template (FIG. 22B) but not into the GA template (FIG. 22C) or the TA template (FIG. 22D). Moreover, the γ -phosphate substituted dUTP analog is not mis-incorporated over the dG or dT in the GA and TA templates, respectively.

[0110] FIGS. 23A-23C are electropherograms and a schematic showing polymerase incorporation of a nucleotide analog and Ag^+ and phosphatase cleavage reactions.

FIG. 23A shows the incorporation of dU onto a primer-target duplex. FIG. 23B shows a nearly quantitative cleavage of the linker with silver ions to the phosphate wherein the peak can be seen to have shifted to the left due to the effect of the loss of the large linker group at the end of the extended fragment. FIG. 23C shows the loss of the phosphate group from the fragment by treatment with Calf Intestine Phosphatase

wherein the peak can be seen to have shifted to the right due to the loss of the negatively charged phosphate group upon cleavage by the phosphatase.

[0111] Additional Examples

[0112] Example 1: Synthesis of propargyl ester of phosphorothiolate linker (**8**) (FIG. 24). Thiophosphoryl trichloride (**4**) (4.7 mL) was added drop-wise to a cooled (-15°C) solution of triethyl phosphate (40 mL) and lutidine (8.7 mL) under argon. Propargyl alcohol (1.7 mL) was then added drop wise and stirred for 1 hr. at -5°C. After cooling to -15°C, the reaction was quenched with 0.5 M tetraethylammonium bicarbonate (TEAB) (100 mL) and stirred for 6 hours at room temperature. The solution was washed with dichloromethane (DCM) two times, and the aqueous phase was concentrated yielding (**5**), which was used without further purification. To 0.76 g of (**5**) in MeOH (10 mL) and water (1 mL) was added methyl-3-(bromomethyl)benzoate (**6**) (0.23 g). After stirring for 2 hr. at room temperature, the reaction mixture was concentrated and the residue was taken in DCM and extracted with water. The DCM layer was concentrated and purified by silica gel column chromatography affording desired pure compound (**7**). A solution of 1:1 ethanol:ethylene diamine (5 mL) was added to 0.1 g of (**7**), the reaction was stirred overnight at 90°C under dry argon, and then evaporated to dryness under high vacuum. The residue was dissolved in 5 mL of methanol, and treated with 0.5 mL of ethyl trifluoroacetate. After 3 hr. at room temperature, the reaction mixture was evaporated to dryness, and purified by column chromatography. Fractions containing (**8**) were identified by mass spectrometry, combined and evaporated to dryness.

[0113] Example 2: Synthesis of dU-5'-monophosphate (**10**) (FIG. 25). To a solution of (**8**) (55 µmol) in DMF (0.6 mL) was added 22 mg of CuI (115 µmol) followed by 44

μL of triethylamine (TEA) (322 μmol) under an argon atmosphere. After all of the CuI had dissolved, 80 μL of a 250 mM solution of Iodo dUMP (**1**) (20 μmol) in DMF was added followed by 23 mg of Pd(PPh₃)₄ (20 μmol). After stirring overnight at room temperature under argon the reaction was diluted with 14 mL of 100 mM TEAA buffer, the suspension was filtered and the supernatant concentrated. The residue was purified by reverse phase HPLC using a triethylammonium acetate (TEAA)/acetonitrile gradient. Fractions containing (**10**) were further purified by anion exchange HPLC using a TEAB/acetonitrile gradient. M/S: (M-H)- 729.2

[0114] Example 3: Synthesis of dC 5'-monophosphate (**12**) (FIG. 26). (**12**) was prepared from (**11**) and (**8**) in a similar manner compared to the synthesis of (**10**) in Example 2.

[0115] Example 4: Synthesis of dA 5'-monophosphate (**14**) (FIG. 27). (**14**) was prepared from (**13**) and (**8**) in a similar manner compared to the synthesis of (**10**) in Example 2.

[0116] Example 5: Synthesis of dG 5'-monophosphate (**16**) (FIG. 28). (**16**) was prepared from (**15**) and (**8**) in a similar manner compared to the synthesis of (**10**) in Example 2.

[0117] Example 6: Synthesis of methylpyrophosphate (**19**) (FIG. 29). 9.1 grams (10 mmol) of tris(tetrabutylammonium) pyrophosphate (**18**) were dissolved in 4.5 mL of acetonitrile and treated with 1.86 grams (10 mmol) of the methyltosylate (**17**). After 30 minutes the reaction was diluted to 100 mL with water and purified on a Dowex 1X8 200 column, equilibrated with 300 mmol tetraethyl ammonium bicarbonate (TEAB), and eluted with a TEAB gradient. The fractions were analyzed for phosphate using a 20 μL portion of each fraction, which was added to 300 μl of 0.5 N HCl in a 13 mm by

100 mm test tube and heated to a boil; 600 μ l of 0.42% solution of ammonium molybdate tetrahydrate in 1 N H_2SO_4 and 100 μ L of a 10% ascorbic acid solution were added to each tube, heated to a boil and then placed in a 40 °C heating block. The tubes that developed blue indicated a phosphate containing fraction. A 2 mL sample from each of these fractions was stripped and examined by ^{31}P NMR for mono-substituted pyrophosphate (^{31}P NMR D_2O (no reference) -8.06 ppm, 2H, dd, $J_1=63.19$, $J_2 = 24.6$).

[0118] Example 7: Synthesis of benzylpyrophosphate (**21**) (FIG. 30). 9.1 grams (10 mmol) of tris(tetrabutylammonium) of pyrophosphate (**18**) was dissolved in 4.5 mL of acetonitrile and treated with 1.71 benzyl bromide (**20**). After 30 minutes the reaction was diluted to 100 mL with water and purified on a Dowex 1X8 200 column, equilibrated with 300 mmol tetraethyl ammonium bicarbonate (TEAB), and eluted with a TEAB gradient. The fractions were analyzed for phosphate using the procedure shown in Example 6. A sample from each of these fractions was stripped and examined by ^{31}P NMR for mono-substituted pyrophosphate (^{31}P NMR D_2O (no reference) ^1H NMR (D_2O) δ 7.3 (m, 5 H), 4.8 (d, 2H)

[0119] Example 8: Synthesis of 2-(N-(3-methylimidazolium))-ethyl pyrophosphate (**25**) (FIG. 31). 4.1 grams, 50 mmol, of methylimidazole (**22**) and 18.5 grams, 50 mmol, of ethylene di(p-toluenesulfonate) (**23**) were heated together for 24 hrs at 70 °C in 50 mL of dry acetonitrile, generating a white precipitate. The suspension was filtered, and the filtrate dried under reduced pressure. The residue was triturated with about 30 ml of methanol, the methanol solution being collected, evaporated to dryness, and crystallized from 30 ml of ethyl acetate. After filtration and vacuum drying, 6.4 grams, of solid white (**24**) was isolated. ^1H NMR (DMSO-d_6) δ 9.06 (s, 1H), 7.68 (d, 2H),

7.61 (t, 2H), 7.48 (d, 2H), 7.46 (d, 2H), 7.11 (d, 2H) 4.47 (t, 2H), 4.41 (t, 2H) 3.81 (s, 3H) 2.42 (s, 3H), 2.18 (s, 3H).

[0120] 14.4 grams of tris(tetrabutylammonium) pyrophosphate of (**18**) were dissolved in 5 mL of acetonitrile and all 6.4 grams of the solid (**24**) was added. After 30 minutes the reaction was diluted into 100 mL of water and loaded on a Dowex 1X8 200 equilibrated with TEAB and eluted with a TEAB gradient. The fractions were analyzed for phosphate using the procedure shown in Example 6. A sample from each of these fractions was stripped and examined by 31 PNMR for mono-substituted pyrophosphate. ¹HNMR (D₂O) δ 8.7 (s, 1H), 7.38 (t, 1H), 7.27 (t, 1H), 4.3 (t, 2 H), 4.09 (m, 2H), 3.74 (s, 3H), 3.1 (q, 6 H), 1.2 (t, 9 H).

[0121] Example 9: Synthesis of γ -methyl-dUTP (**26**) (FIG. 32). Tri-n-butylamine (2.2 μ L, 9.3 μ mol) was added to a dimethylformamide (DMF) solution (0.2 mL) of methyl pyrophosphate (**19**) (1.2 mg, 5 μ mol from Example 2) that was previously co-evaporated two times with anhydrous DMF (0.2 mL). Carbonyldiimidazole (CDI, 4 mg, 25 μ mol) was added and the mixture was stirred at room temperature overnight. Excess CDI was destroyed by addition of MeOH (2.2 μ L) and stirring for 30 minutes. To the resulting mixture was added (**19**) from Example 6 (0.5 μ mol in 0.1 mL DMF), which was stirred at room temperature for 3 days. After concentration at reduced vacuum, the residue was purified on anion exchange HPLC with an acetonitrile/TEAB gradient. The fractions containing (**26**) were combined and further purified by reverse phase HPLC: M/S: M-1 = 779.2 (calc. 779.0)

[0122] Example 10: Synthesis of γ -benzyl-dATP (**27**) (FIG. 33). This compound was assembled and purified in a similar manner compared to Example 9, using pyrophosphate (**27**) from Example 7 and dAMP (**14**) from Example 4.

[0123] Example 11: Synthesis of γ -(2-(N-(3-methylimidazolium))-ethyl)-dCTP (**28**) (FIG. 34). This compound was assembled and purified in a similar manner compared to Example 9, using pyrophosphate (**25**) from Example 8 and dCMP (**12**) from Example 3.

[0124] Example 12: Synthesis of γ -(2-(N-(3-methylimidazolium))-ethyl)-dGTP (**29**) (FIG. 35). This compound was assembled and purified in a similar manner compared to Example 9, using pyrophosphate (**25**) from Example 8 and dGMP (**16**) from Example 5.

[0125] Example 13: General procedure for evaluation of termination properties of γ -substituted-dNTP's comprising silver ion cleavable linker arms attached to the base. All evaluations performed with Terminator (NEB) DNA polymerases were 3' to 5' exonuclease negative. Three types of templates were used in testing each substrate, where **N** denotes the complement of the base that is being evaluated for its termination properties, and the underlined portion of the target is the priming site: 1) a single correct base immediately after the priming site followed by incorrect bases; 2) two correct bases immediately after the priming site followed by incorrect bases; 3) each incorrect base followed by the correct base and then additional incorrect bases. The first two primers were used to show incorporation and termination, while the third set of templates was used to study mis-incorporation. All substrates were evaluated by capillary electrophoresis with analysis for extension of 0, 1, or 2 bases from a fluorescein labeled -21 M13 primer (the binding site of the primer corresponds to the underlined portion of the templates shown below).

1. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTTNACTGGCCGTCGTTTTACA [SEQ ID NO: 7]
2. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTNNACTGGCCGTCGTTTTACA [SEQ ID NO: 8]
3. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTNTACTGGCCGTCGTTTTACA [SEQ ID NO: 9]

(BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTNCACTGGCCGTCGTTTTACA [SEQ ID NO: 10]

(BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTNGACTGGCCGTCGTTTTACA: [SEQ ID NO: 11]

(BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTNAACTGGCCGTCGTTTTACA: [SEQ ID NO: 12]

[0126] Templates were pre-hybridized to the primer at 2 μ M final concentration. The final assay concentration of the primer/template hybrid was 40 nM.

[0127] Unless otherwise noted, substrates were tested at 1 μ M final concentration with 1 μ L of the appropriate commercial enzyme at the concentration supplied by the manufacturer (usually 2-5 U/ μ L in 2X buffer composed of 40 mM Tris, pH 7.6, 10 mM DTT, 10 mM Mg₂SO₄ and 30 mM isocitrate). Each buffer was used at 1X in the final assay.

[0128] Generally, assays were set up as 10 μ L final volume and run at 65°C. The termination properties were evaluated at 10 minutes, 30 minutes and 1 hr. At the end of each reaction, 4 mL of the reaction mix was pipetted into 25 μ L of 0.5 M EDTA, to quench the reaction, in a streptavidin coated microtiter plate well (Applied Biosystems Part No. 4357279) to capture the biotin labeled template for purification of the primer. Plates were shaken at room temperature for 10 minutes. Excess fluid was discarded and the microtiter wells were washed 3X with 4X SSC containing 0.1% Tween 20. Plates were centrifuged briefly upside down to remove excess buffer. To remove the primer from the template, 20 μ L of HiDi Formamide (Applied Biosystems Part No. 4311320) was added with size ladder (LIZ® dye-labeled SNPlex™ internal size standard) to each well. The plate was incubated at 50°C with shaking for 10 minutes. 10 mL of the HiDi Formamide solution was transferred to a 96 well plate (Applied Biosystems Part No. N8010560) and covered with a 96 well plate septa (Applied Biosystems Part No. 4315933). Samples were separated electrophoretically on an AB 3100XL with a 36 cm capillary with POP6™ polymer separating media. The peaks

were analyzed with either GeneScan® Software or Peak Scanner™ software, both from Applied Biosystems.

[0129] Example 14: Termination and mis-incorporation properties of γ -methyl-dUTP (26). The substrate from Example 9 was evaluated following the procedure of Example 13, using the following templates.

1. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTTAACTGGCCGTCGTTTTACA [SEQ ID NO: 13]
2. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTAACTGGCCGTCGTTTTACA [SEQ ID NO: 4]
3. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTATACTGGCCGTCGTTTTACA [SEQ ID NO: 14]
- (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTAGACTGGCCGTCGTTTTACA [SEQ ID NO: 15]

[0130] Termination properties are shown in FIG. 21 and mis-incorporation properties are shown in FIG. 22. FIG. 21 shows almost complete consumption of the primer after 10 minutes. No further incorporation is observed over the 2nd A of template 2 after 60-minutes, indicating excellent termination properties.

[0131] Example 15: Termination and mis-incorporation properties of γ -benzyl-dATP (27). The substrate from Example 10 was evaluated following the procedure of Example 13, using the following templates.

1. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTATACTGGCCGTCGTTTTACA [SEQ ID NO: 14]
2. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTTTACTGGCCGTCGTTTTACA [SEQ ID NO: 16]
3. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTTAACTGGCCGTCGTTTTACA [SEQ ID NO: 13]
- (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTTGACTGGCCGTCGTTTTACA [SEQ ID NO: 17]
- (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTTCACTGGCCGTCGTTTTACAZ [SEQ ID NO: 18]

[0132] Termination and mis-incorporation properties are shown in FIG. 36. FIG. 36 shows almost complete consumption of the primer after 10 minutes; no further incorporation is observed over the 2nd T of template 2 after 60 minutes, indicating excellent termination properties.

[0133] Example 16: Termination and mis-incorporation properties of γ -imidazolium-dCTP (**28**). The substrate from Example 11 was evaluated following the procedure of example 13, using the following templates.

1. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTCGACTGGCCGTCGTTTTACA [SEQ ID NO: 19]
2. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTGGACTGGCCGTCGTTTTACA [SEQ ID NO: 20]
3. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTGAACTGGCCGTCGTTTTACA [SEQ ID NO: 21]
- (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTGTACTGGCCGTCGTTTTACA [SEQ ID NO: 22]
- (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTGCACTGGCCGTCGTTTTACA [SEQ ID NO: 23]

[0134] Termination and mis-incorporation properties at 1 μ M [(**28**)] are shown in FIG. 37. As can be seen from FIG. 37, the activity of (**28**) is quite low, significant incorporation of (**28**) is observed after 1 hr. and no mis-incorporation is observed after 1 hr. Termination properties of (**28**) at higher concentrations are shown in FIG. 38. As can be seen from FIG. 38, at 5 μ M [(**28**)] the primer is completely consumed after 30 minutes, with only a trace of extension past the first base on the **GG** template.

[0135] Example 17: Termination and mis-incorporation properties of γ -imidazolium-dGTP (**29**). The substrate from Example 12 was evaluated following the procedure of Example 13, using the following templates.

1. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTGCACTGGCCGTCGTTTTACA [SEQ ID NO: 23]
2. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTCCACTGGCCGTCGTTTTACA [SEQ ID NO: 24]
3. (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTCAACTGGCCGTCGTTTTACA [SEQ ID NO: 25]
- (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTCGACTGGCCGTCGTTTTACA [SEQ ID NO: 19]
- (BIO-TEG)(C18)(C18)CCCCCGTGTGTGCTCTACTGGCCGTCGTTTTACA [SEQ ID NO: 26]


[0136] Termination and mis-incorporation properties at 1 μ M [(**29**)] are shown in FIG. 39. As can be seen from FIG. 39, the activity of (**29**) is quite low, significant incorporation of (**29**) is observed only after 1 hr. and no mis-incorporation is observed after 1 hr. Termination properties of (**29**) at higher concentrations are shown in FIG.

40. As can be seen from FIG. 40, at 4 μ M [(29)] the primer is completely consumed after 1 hr., with only a trace of extension past the first base on the CC template.

[0137] While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be appreciated by one skilled in the art from reading this disclosure that various changes in form and detail can be made without departing from the true scope of the invention.

WHAT IS CLAIMED IS:

1. A compound represented by the following formula (I):



wherein:

B is a base selected from the group consisting of adenine, guanine, cytosine, uracil, thymine, or their respective analogs;

L₁ is a group that forms a linkage between the base B and F;

F is a heteroatom that forms a linkage between L₁ and L₂;

L₂ is a chemically labile group with respect to its attachment to F and forms a chemical linkage to R₂;

L₃ is a chemically labile group with respect to its attachment to F and forms a chemical linkage to R₂;

R₂ is a group comprising a reporter;

R₁ is a group that suppresses the template directed polymerase incorporation rate of the nucleoside triphosphate onto the 3' end of an extending oligonucleotide prior to cleavage of L₂-R₂ from the previous incorporation event;

L₂-R₂ prevents the template directed polymerase incorporation of the compound of the formula (I) onto the 3' end of an extending oligonucleotide onto which a compound of the formula (I) has been incorporated;

l is an integer; and

$$m = 3l - 1.$$

2. The compound of claim 1 where R_1 is an organic substituent selected from the group consisting of neutral forms of substituted or un-substituted alkyls, substituted or un-substituted aromatics, substituted or un-substituted heterocycles, substituted or un-substituted aromatic heterocycles, or anionic or cationic forms thereof.


3. The compound of Claim 2, wherein cleavage of the chemically labile group L_2 leaves a linker residue moiety attached to the base having a terminal group F.

4. The compound of Claim 3, wherein the terminal group F is not an amino group.

5. The compound of Claim 3, wherein the terminal group F is an hydroxyl group.

6. The compound of Claim 1, wherein l is 2 or 3.

7. The compound of Claim 1, wherein the compound has a structure represented by the following formula (II):



8. The compound of Claim 1, wherein L_2 comprises a chemically labile group selected from the group consisting of: $-C(O)-S-$; $-C(O)O-$; $-CH-(SCH_3)-Ph-$ and $[RO]_2P(O)S-$; wherein Ph is a substituted phenyl group or a substituted aromatic ring; and wherein R_1 is an organic substituent selected from the group consisting of neutral

forms of substituted or un-substituted alkyls, substituted or un-substituted aromatics, substituted or un-substituted heterocycles, substituted or un-substituted aromatic heterocycles, or anionic or cationic forms thereof.


9. The compound of Claim 2, wherein L_1 forms a permanent linkage between the base and the heteroatom F, and L_2 forms a transient linkage between the heteroatom F and R_2 .

10. The compound of Claim 9, wherein the heteroatom is O, S, or N.


11. The compound of Claim 9, wherein L_1 comprises a moiety represented by the formula:




12. The compound of Claim 9, wherein L_1 comprises a moiety represented by the formula:



13. The compound of Claim 9, wherein L_2 - R_2 comprises a moiety represented by the formula:







14. The compound of Claim 1, wherein the compound has a structure represented by the following formula (VI):




wherein "Dye" represents the reporter.

15. The compound of Claim 1, wherein the chemically labile group L_2 is activated by Ag^+ to cleave F- L_2 .

16. The compound of Claim 1, wherein L_2 comprises a moiety selected from the group consisting of:



17. The compound of Claim 1, wherein L_2 comprises a moiety of the following formula:



18. A method of sequencing a nucleic acid comprising:

(a) hybridizing a primer to a target polynucleotide to form a primer-target duplex, wherein the target polynucleotide is attached to a solid support at the 3' or 5' end;

(b) contacting the primer-target duplex with a polymerase and one or more nucleotide analogs to incorporate a nucleotide analog onto the 3' end of the primer thereby forming an extended primer strand, wherein the incorporated nucleotide analog terminates the polymerase reaction and wherein each of the one or more nucleotide analogs comprises: (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine, uracil and their analogs; (ii) a label attached to the base or analog thereof via a cleavable linker; (iii) a deoxyribose; and (iv) one or more phosphate groups, wherein the label is unique for the base and wherein the combination of a polyphosphate terminal substituent, the linker and/or the label inhibits the template directed polymerase incorporation of a further nucleotide analog onto the extended primer strand;

(c) washing the surface of the solid support to remove unincorporated nucleotide analogs;


(d) detecting the unique label attached to the just-incorporated nucleotide analog to thereby identify the just-incorporated nucleotide analog;

(e) cleaving the cleavable linker between the just incorporated nucleotide analog and the unique label thereby allowing the incorporation of a further nucleotide analog onto the extended primer strand;

(f) washing the surface of the solid support to remove cleaved compound fragments; and

(e) repeating steps (b), (c), (d), (e) and (f).

19. The method of Claim 18, wherein each of the one or more nucleotide analogs has a structure represented by the following formula (I):



wherein:

B is a base selected from the group consisting of adenine, guanine, cytosine, uracil, thymine, or their respective analogs;

L₁ is a group that forms a linkage between the base B and F;

F is a heteroatom that forms a linkage between L₁ and L₂;

L₂ is a chemically labile group with respect to its attachment to F and forms a chemical linkage to R₂;

L₃ is a chemically labile group with respect to its attachment to F and forms a chemical linkage to R₂;

R₂ is a group comprising a reporter;

R₁ is a group that suppresses the template directed polymerase incorporation rate of the nucleoside triphosphate onto the 3' end of an extending oligonucleotide prior to cleavage of L₂-R₂ from the previous incorporation event;

L_2-R_2 prevents the template directed polymerase incorporation of the compound of the formula (I) onto the 3' end of an extending oligonucleotide onto which a compound of the formula (I) has been incorporated;

l is an integer; and

$m = 3l - 1$.

20. The method of Claim 19, wherein R_1 is an organic substituent selected from the group consisting of neutral forms of substituted or un-substituted alkyls, substituted or un-substituted aromatics, substituted or un-substituted heterocycles, substituted or un-substituted aromatic heterocycles, or anionic or cationic forms thereof, L_3 is H, l is 2, and m is 5.

21. The method of Claim 19, wherein the one or more nucleotide analogs comprise: a first nucleotide analog wherein B is adenine having a first label; a second nucleotide analog wherein B is guanine having a second label; a third nucleotide analog wherein B is cytosine having a third label; and a fourth nucleotide analog wherein B is thymine having a fourth label.

22. The method of Claim 21, wherein the first, second, third and fourth labels are each fluorescent labels.


23. The method of Claim 19, wherein R_1 is a group that suppresses the template directed polymerase incorporation rate of the nucleoside triphosphate onto the 3' end of an extending oligonucleotide prior to cleavage of L_2-R_2 from the previous incorporation event.

24. The method of Claim 23, wherein R_1 is a reporter or quencher.

25. The compound of Claim 1, wherein R_1 is a group that suppresses the template directed polymerase incorporation rate of the nucleoside triphosphate onto the 3' end of an extending oligonucleotide prior to cleavage of L_2-R_2 from the previous incorporation event.

26. The compound of Claim 25, wherein R_1 is a reporter or quencher.

27. The compound of Claim 1, wherein the compound has a structure represented by the following formula (VI):



wherein R_1 is not H.


28. The compound of Claim 27, wherein R_1

is an organic substituent selected from the group consisting of neutral forms of substituted or un-substituted alkyls, substituted or un-substituted aromatics, substituted or un-substituted heterocycles, substituted or un-substituted aromatic heterocycles, or anionic or cationic forms thereof.

29. The compound of Claim 7, wherein R_1 is not H.

30. The compound of Claim 29, wherein R_1 is an organic substituent selected from the group consisting of neutral forms of substituted or un-substituted alkyls, substituted or un-substituted aromatics, substituted or un-substituted heterocycles, substituted or un-substituted aromatic heterocycles, or anionic or cationic forms thereof.

31. The method of Claim 18, wherein each of the one or more nucleotide analogs has a structure represented by the following formula (II):




wherein R_1 is not H.


32. The method of Claim 31, wherein R_1 is a substituted or un-substituted hydrocarbon group.

33. The method of Claim 32, wherein R_1 is a substituted or un-substituted methyl, propargyl or benzyl group.

34. The method of Claim 31, wherein each of the one or more nucleotide analogs has a structure represented by the following formula (VI):




wherein R_1 is not H.



1



FIG. 2A



2





FIG. 2B



FOR F = -N-, n = 1
FOR F = -O-, m = >20

FIG. 3




FIG. 4




FIG. 5B




FIG. 5A

7/50




FIG. 5C




FIG. 5D




FIG. 6




FIG. 8

11/50




FIG. 9A




FIG. 9B

12/50




FIG. 9C




FIG. 9D

13/50




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D

14/50




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 17A




FIG. 17B




FIG. 18

23/50




FIG. 19




FIG. 20







FIG. 21



C



D

FIG. 21






FIG. 22



C



D

FIG. 22




FIG. 23








FIG. 24




(10)

FIG. 25



(12)

FIG. 26



(14)

(13)

FIG. 27




FIG. 28




FIG. 29




FIG. 32




FIG. 33




FIG. 34




FIG. 35

36/50




FIG. 36A

37/50




FIG. 36B

38/50





FIG. 36C






FIG. 37B




FIG. 37C

42/50
10 MIN




FIG. 38A

43/50
30 MIN




FIG. 38B

44/50

1 HR




FIG. 38C

45/50




FIG. 39A

46/50




FIG. 39B

47/50




FIG. 39C

48/50




FIG. 40A

49/50




FIG. 40B

50/50




FIG. 40C

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2009/031297

A. CLASSIFICATION OF SUBJECT MATTER INV. C07H19/073 C07H21/04 C12Q1/68 C07H19/173		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07H C12Q		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, CHEM ABS Data, BEILSTEIN Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00/36152 A (LI COR INC [US]; WILLIAMS JOHN G K [US]) 22 June 2000 (2000-06-22) page 5, lines 17-19 page 7, lines 29-31 claim 1; figures 1-3	1-34
A	US 2007/117103 A1 (BUZBY PHILIP R [US]) 24 May 2007 (2007-05-24) paragraphs [0005], [0008], [0009], [0049] - [0052]; claims 1,10; figures 1-6C ----- -/--	1-34
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents :		
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family	
Date of the actual completion of the international search	Date of mailing of the international search report	
17 April 2009	08/05/2009	
Name and mailing address of the ISA/ European Patent Office, P.B. 5318 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Nikolai, Joachim	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2009/031297

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of Item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
 - a. type of material
 - a sequence listing
 - table(s) related to the sequence listing
 - b. format of material
 - on paper
 - in electronic form
 - c. time of filing/furnishing
 - contained in the international application as filed
 - filed together with the international application in electronic form
 - furnished subsequently to this Authority for the purpose of search
2. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2009/031297

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>JU JINGYUE ET AL: "Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 103, no. 52, 1 January 2006 (2006-01-01), pages 19635-19640, XP002461564 ISSN: 0027-8424 cited in the application figure 1</p>	1-34
A	<p>LI ZENGMIN ET AL: "A photocleavable fluorescent nucleotide for DNA sequencing and analysis"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 100, no. 2, 21 January 2003 (2003-01-21), pages 414-419, XP002408035 ISSN: 0027-8424 scheme 1</p>	1-34

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2009/031297

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0036152 A	22-06-2000	AT 319857 T	15-03-2006
		AU 2180200 A	03-07-2000
		AU 772281 B2	22-04-2004
		AU 2360200 A	03-07-2000
		CA 2355816 A1	22-06-2000
		DE 69930310 T2	28-12-2006
		EP 1141409 A1	10-10-2001
		JP 2002532104 T	02-10-2002
		WO 0036151 A1	22-06-2000

US 2007117103 A1	24-05-2007	NONE	